
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
LabCorp has announced that Covance, its drug development business, has created COVID-19 Clinical Trial Connect in the U.S., a site designed to help people access information about how to participate in COVID-19 research. Through the Covance COVID-19 Clinical Trial Connect site, prospective patients would be notified of studies run by Covance on behalf of a biopharmaceutical company, as well as those listed in
For more information, click






